West Pharmaceutical Services (NYSE:WST) Reaches New 1-Year High – Here’s Why

West Pharmaceutical Services, Inc. (NYSE:WST)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $367.66 and last traded at $360.9680, with a volume of 546894 shares changing hands. The stock had previously closed at $365.74.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Stephens reaffirmed an “overweight” rating and issued a $360.00 target price on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Morgan Stanley boosted their price target on shares of West Pharmaceutical Services from $315.00 to $325.00 and gave the company an “equal weight” rating in a report on Friday, May 29th. KeyCorp increased their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Evercore reiterated an “outperform” rating and issued a $410.00 price objective on shares of West Pharmaceutical Services in a research report on Monday. Finally, Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $351.91.

West Pharmaceutical Services Stock Performance

The stock has a market cap of $25.16 billion, a price-to-earnings ratio of 47.61, a PEG ratio of 2.99 and a beta of 1.16. The company’s 50 day simple moving average is $324.62 and its 200 day simple moving average is $280.17. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. The company had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.67 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the sale, the vice president owned 16,828 shares in the company, valued at $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the transaction, the chief accounting officer directly owned 1,523 shares of the company’s stock, valued at $457,920.41. This represents a 37.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On West Pharmaceutical Services

Institutional investors and hedge funds have recently bought and sold shares of the business. 55 North Private Wealth LLC acquired a new position in shares of West Pharmaceutical Services in the 2nd quarter worth approximately $241,000. GAMMA Investing LLC boosted its holdings in West Pharmaceutical Services by 19.7% during the second quarter. GAMMA Investing LLC now owns 4,095 shares of the medical instruments supplier’s stock worth $1,470,000 after buying an additional 674 shares in the last quarter. Versant Capital Management Inc boosted its holdings in West Pharmaceutical Services by 78.9% during the second quarter. Versant Capital Management Inc now owns 1,032 shares of the medical instruments supplier’s stock worth $370,000 after buying an additional 455 shares in the last quarter. CX Institutional grew its position in West Pharmaceutical Services by 22.6% in the second quarter. CX Institutional now owns 1,328 shares of the medical instruments supplier’s stock worth $477,000 after buying an additional 245 shares during the last quarter. Finally, Eastern Bank grew its position in West Pharmaceutical Services by 57.5% in the second quarter. Eastern Bank now owns 430 shares of the medical instruments supplier’s stock worth $154,000 after buying an additional 157 shares during the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.